ZA200608412B - Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor - Google Patents

Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor

Info

Publication number
ZA200608412B
ZA200608412B ZA200608412A ZA200608412A ZA200608412B ZA 200608412 B ZA200608412 B ZA 200608412B ZA 200608412 A ZA200608412 A ZA 200608412A ZA 200608412 A ZA200608412 A ZA 200608412A ZA 200608412 B ZA200608412 B ZA 200608412B
Authority
ZA
South Africa
Prior art keywords
dihydroisoindol
furo
pyrrol
aza
bicyclo
Prior art date
Application number
ZA200608412A
Other languages
English (en)
Inventor
Chapdelaine Marc
Keith J Herzog
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200608412B publication Critical patent/ZA200608412B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200608412A 2004-04-14 2006-10-09 Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor ZA200608412B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
ZA200608412B true ZA200608412B (en) 2008-09-25

Family

ID=32294312

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608412A ZA200608412B (en) 2004-04-14 2006-10-09 Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor

Country Status (14)

Country Link
US (1) US7566727B2 (ru)
EP (1) EP1737854A1 (ru)
JP (1) JP2007532637A (ru)
CN (1) CN1968951A (ru)
AU (1) AU2005233492B2 (ru)
BR (1) BRPI0509777A (ru)
CA (1) CA2563010A1 (ru)
IL (1) IL178241A0 (ru)
NO (1) NO20065199L (ru)
RU (2) RU2372350C2 (ru)
SE (1) SE0400970D0 (ru)
UA (1) UA86617C2 (ru)
WO (1) WO2005100351A1 (ru)
ZA (1) ZA200608412B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
EP2470183B1 (en) * 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CA2785499C (en) * 2009-12-22 2017-05-02 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
MX2012007692A (es) 2009-12-31 2013-05-20 Piramal Healthcare Ltd Inhibidores del diacilglicerol acil transferasa.
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
WO2017112719A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
CN110099907A (zh) 2016-12-21 2019-08-06 拜欧赛里克斯公司 靶向蛋白质的噻吩并吡咯衍生物、组合物、方法及其用途
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018210229A1 (zh) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 α-7尼古丁乙酰胆碱受体激动剂及应用
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
US10945771B2 (en) * 2017-06-09 2021-03-16 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
SE9201478D0 (sv) * 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
IT1303123B1 (it) * 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002044176A1 (en) * 2000-12-01 2002-06-06 Neurosearch A/S 3-substituted quinuclidines and their use as nicotinic agonists
DE10118551A1 (de) * 2001-04-14 2002-10-17 Merck Patent Gmbh Nikotinische Acetylcholinrezeptor Liganden
EP1406900B1 (en) * 2001-07-06 2006-10-04 Neurosearch A/S Novel compounds, their preparation and use
AU2003250322B2 (en) 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use

Also Published As

Publication number Publication date
RU2009126341A (ru) 2011-01-20
CN1968951A (zh) 2007-05-23
SE0400970D0 (sv) 2004-04-14
WO2005100351A1 (en) 2005-10-27
AU2005233492B2 (en) 2009-06-11
US20070213342A1 (en) 2007-09-13
NO20065199L (no) 2006-11-13
US7566727B2 (en) 2009-07-28
BRPI0509777A (pt) 2007-10-23
IL178241A0 (en) 2006-12-31
RU2372350C2 (ru) 2009-11-10
EP1737854A1 (en) 2007-01-03
AU2005233492A1 (en) 2005-10-27
CA2563010A1 (en) 2005-10-27
JP2007532637A (ja) 2007-11-15
RU2006135481A (ru) 2008-05-20
UA86617C2 (en) 2009-05-12

Similar Documents

Publication Publication Date Title
ZA200608412B (en) Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
HUP0401849A3 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
IL172762A0 (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
HK1045512A1 (en) Tetracyclic azepinoindole compounds as 5-ht receptor ligands.
HUS1400056I1 (hu) Glükopiranozil-helyettesített benzol-származékok, az említett vegyületeket tartalmazó gyógyszerek, azok alkalmazása, és eljárás elõállításukra
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DK1147112T3 (da) Diazabicykliske derivater som nicotiniske acetylcholinreceptorligander
AP2213A (en) Muscarinic acetylcholine receptor antagonists.
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
ZA200306341B (en) Imidazo (1,2-a)-pyridine derivatives as mGluR5 antagonists.
EP1828180A4 (en) 1H-pyrrolo [2,3-BETA] PYRIDINE
DE122012000043I1 (de) Pyrrolo[2,3-B]pyridinderivate als proteinkinaseinhibitoren.
IL183603A0 (en) Nicotinic acetylcholine receptor ligands
IL175993A0 (en) Nicotinic acetylcholine receptor ligands
PT1838683E (pt) Um processo para a preparação de derivados de [1,4,5]-oxadiazepina
HK1079708A1 (zh) 可用作毒蕈碱性受體拮抗劑的3，6-二取代氮雜二環[3．1．10]己烷衍生物
MXPA03002076A (es) Derivados de (2-azabiciclo(2.2.1)hept-7-il) metanol como agonistas de receptores nicotinicos de acetilcolina.
IL176073A0 (en) Nicotinic acetylcholine receptor ligands
DK1784403T3 (da) Pyrrolo[3,2-b]pyridinderivater samt fremgangsmåder til deres fremstilling
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
HUP0304034A2 (hu) Nikotin acetilkolin receptor ligandumokként és/vagy szerotonerg ligandumokként alkalmazható 6H-oxazolo[4,5-e]indol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL176071A0 (en) Nicotinic acetylcholine receptor ligands
ZA200705106B (en) Nicotinic acetycholine receptor ligands
DK1593682T3 (da) 4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazin-6-carboxarnid-forbindelser, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende disse.
AU2531101A (en) 9-azabicyclo(4.2.1)non-2-ene derivatives as ligands for nicotinic acetylcholine receptors